ONVO Stock Overview
A biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Organovo Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.45 |
| 52 Week High | US$2.05 |
| 52 Week Low | US$0.43 |
| Beta | 0.61 |
| 11 Month Change | -16.96% |
| 3 Month Change | -37.83% |
| 1 Year Change | -62.77% |
| 33 Year Change | -93.05% |
| 5 Year Change | -92.42% |
| Change since IPO | -98.64% |
Recent News & Updates
Recent updates
Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?
Feb 10
Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation
Aug 24We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely
May 10We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely
Jan 04Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside
May 28Shareholder Returns
| ONVO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.6% | -2.6% | -0.7% |
| 1Y | -62.8% | 17.5% | 30.3% |
Return vs Industry: ONVO underperformed the US Biotechs industry which returned 18.4% over the past year.
Return vs Market: ONVO underperformed the US Market which returned 32.2% over the past year.
Price Volatility
| ONVO volatility | |
|---|---|
| ONVO Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ONVO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ONVO's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 20 | n/a | www.organovo.com |
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company’s lead candidate is FXR314, which is phase 2/3 clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus on non-alcoholic steatohepatitis and primary biliary cholangitis.
Organovo Holdings, Inc. Fundamentals Summary
| ONVO fundamental statistics | |
|---|---|
| Market cap | US$7.16m |
| Earnings (TTM) | -US$13.99m |
| Revenue (TTM) | US$73.00k |
94.7x
P/S Ratio-0.5x
P/E RatioIs ONVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONVO income statement (TTM) | |
|---|---|
| Revenue | US$73.00k |
| Cost of Revenue | US$5.24m |
| Gross Profit | -US$5.16m |
| Other Expenses | US$8.82m |
| Earnings | -US$13.99m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | -7,072.60% |
| Net Profit Margin | -19,160.27% |
| Debt/Equity Ratio | 0% |
How did ONVO perform over the long term?
See historical performance and comparison